COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
Identifieur interne : 001962 ( Main/Corpus ); précédent : 001961; suivant : 001963COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
Auteurs : Abdurrahman Tufan ; Aslihan Avano Lu Güler ; Marco Matucci-CerinicSource :
- Turkish journal of medical sciences [ 1303-6165 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (therapeutic use), Antirheumatic Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Cytokines (immunology), Drug Repositioning (MeSH), Humans (MeSH), Immune System (MeSH), Immunity, Cellular (MeSH), Immunosuppressive Agents (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , immunology : Cytokines.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antirheumatic Agents, Immunosuppressive Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Repositioning, Humans, Immune System, Immunity, Cellular, Pandemics, SARS-CoV-2.
Abstract
In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines “cytokine storm” leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.
DOI: 10.3906/sag-2004-168
PubMed: 32299202
PubMed Central: PMC7195984
Links to Exploration step
pubmed:32299202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs</title><author><name sortKey="Tufan, Abdurrahman" sort="Tufan, Abdurrahman" uniqKey="Tufan A" first="Abdurrahman" last="Tufan">Abdurrahman Tufan</name><affiliation><nlm:affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</nlm:affiliation></affiliation></author><author><name sortKey="Avano Lu Guler, Aslihan" sort="Avano Lu Guler, Aslihan" uniqKey="Avano Lu Guler A" first="Aslihan" last="Avano Lu Güler">Aslihan Avano Lu Güler</name><affiliation><nlm:affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</nlm:affiliation></affiliation></author><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32299202</idno><idno type="pmid">32299202</idno><idno type="doi">10.3906/sag-2004-168</idno><idno type="pmc">PMC7195984</idno><idno type="wicri:Area/Main/Corpus">001962</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001962</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs</title><author><name sortKey="Tufan, Abdurrahman" sort="Tufan, Abdurrahman" uniqKey="Tufan A" first="Abdurrahman" last="Tufan">Abdurrahman Tufan</name><affiliation><nlm:affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</nlm:affiliation></affiliation></author><author><name sortKey="Avano Lu Guler, Aslihan" sort="Avano Lu Guler, Aslihan" uniqKey="Avano Lu Guler A" first="Aslihan" last="Avano Lu Güler">Aslihan Avano Lu Güler</name><affiliation><nlm:affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</nlm:affiliation></affiliation></author><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy</nlm:affiliation></affiliation></author></analytic><series><title level="j">Turkish journal of medical sciences</title><idno type="eISSN">1303-6165</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Cytokines (immunology)</term><term>Drug Repositioning (MeSH)</term><term>Humans (MeSH)</term><term>Immune System (MeSH)</term><term>Immunity, Cellular (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antirheumatic Agents</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Drug Repositioning</term><term>Humans</term><term>Immune System</term><term>Immunity, Cellular</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines “cytokine storm” leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32299202</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1303-6165</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>SI-1</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>21</Day></PubDate></JournalIssue><Title>Turkish journal of medical sciences</Title><ISOAbbreviation>Turk J Med Sci</ISOAbbreviation></Journal><ArticleTitle>COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs</ArticleTitle><Pagination><MedlinePgn>620-632</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3906/sag-2004-168</ELocationID><Abstract><AbstractText>In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines “cytokine storm” leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.</AbstractText><CopyrightInformation>This work is licensed under a Creative Commons Attribution 4.0 International License.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tufan</LastName><ForeName>Abdurrahman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6244-9362</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avanoğlu Güler</LastName><ForeName>Aslihan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9866-9797</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matucci-Cerinic</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9324-3161</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk J Med Sci</MedlineTA><NlmUniqueID>9441758</NlmUniqueID><ISSNLinking>1300-0144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">cytokine storm</Keyword><Keyword MajorTopicYN="Y">inflammation</Keyword><Keyword MajorTopicYN="Y">rheumatology</Keyword><Keyword MajorTopicYN="Y">treatment</Keyword><Keyword MajorTopicYN="Y">antiinflammatory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32299202</ArticleId><ArticleId IdType="doi">10.3906/sag-2004-168</ArticleId><ArticleId IdType="pmc">PMC7195984</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med J Aust. 2020 May;212(9):416-420</Citation><ArticleIdList><ArticleId IdType="pubmed">32266987</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2011 Nov 25;420(2):106-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21959016</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Jan 12;271(5246):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8539616</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54</Citation><ArticleIdList><ArticleId IdType="pubmed">30806709</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1992 Dec 25;267(36):25744-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1464591</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2007 May;46(5):808-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17202178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation><ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015;70(6):1608-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25693996</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2010 Aug;2(8):1804-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21994708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2020 May 11;221(11):1762-1769</Citation><ArticleIdList><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2014 May 01;10(5):e1004077</Citation><ArticleIdList><ArticleId IdType="pubmed">24788150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 12;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 Feb;46(2):315-328</Citation><ArticleIdList><ArticleId IdType="pubmed">32040667</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci China C Life Sci. 2009 May;52(5):464-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19471869</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Jan;149:143-149</Citation><ArticleIdList><ArticleId IdType="pubmed">29175128</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2019 Dec 26;381(26):2497-2505</Citation><ArticleIdList><ArticleId IdType="pubmed">31733140</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2012 May;4(5):833-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Oct 14;401(6754):708-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10537110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2006;11(8):1021-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17302372</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2020 Jul;158(1):55-56</Citation><ArticleIdList><ArticleId IdType="pubmed">32243944</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2015 Nov;485:330-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26331680</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 2;395(10234):1407-1409</Citation><ArticleIdList><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2015 Mar;115:21-38</Citation><ArticleIdList><ArticleId IdType="pubmed">25554382</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2019 Jan 29;10:50</Citation><ArticleIdList><ArticleId IdType="pubmed">30761102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jul;83(14):7221-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19420077</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2019 May 27;16(1):69</Citation><ArticleIdList><ArticleId IdType="pubmed">31133031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45</Citation><ArticleIdList><ArticleId IdType="pubmed">32251729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208</Citation><ArticleIdList><ArticleId IdType="pubmed">32164089</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2011 Feb;42(1):37-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20976535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):648-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Reumatismo. 2015 Dec 30;67(3):849</Citation><ArticleIdList><ArticleId IdType="pubmed">26876193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2000 Apr;81(Pt 4):853-79</Citation><ArticleIdList><ArticleId IdType="pubmed">10725411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2010 Jul;10(7):490-500</Citation><ArticleIdList><ArticleId IdType="pubmed">20559327</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180</Citation><ArticleIdList><ArticleId IdType="pubmed">32207680</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 1997 Jul;25(7):1115-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9233735</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathogens. 2020 Mar 04;9(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">32143502</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation><ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 2006;66:193-292</Citation><ArticleIdList><ArticleId IdType="pubmed">16877062</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2015 Apr 03;7(4):1700-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25855243</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2008 May 30;133(5):775-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18510923</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2014 Apr 26;383(9927):1503-1516</Citation><ArticleIdList><ArticleId IdType="pubmed">24290661</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation><ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18490652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 31;34(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32228825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Struct Biol. 2011 Apr;174(1):11-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21130884</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2020 May;109:102433</Citation><ArticleIdList><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation><ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecancermedicalscience. 2020 Mar 27;14:1022</Citation><ArticleIdList><ArticleId IdType="pubmed">32256705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation><ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId></ArticleIdList></Reference><Reference><Citation>Virusdisease. 2020 Mar;31(1):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">32206694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:320-327</Citation><ArticleIdList><ArticleId IdType="pubmed">29207305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 May;79(5):668-669</Citation><ArticleIdList><ArticleId IdType="pubmed">32241792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2020 Feb 21;5(1):18</Citation><ArticleIdList><ArticleId IdType="pubmed">32296012</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2016 Feb;44(2):275-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26584195</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 Jun;19(6):102537</Citation><ArticleIdList><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2016 Apr 21;16:174</Citation><ArticleIdList><ArticleId IdType="pubmed">27097824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(9):5288-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15827143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2014 Jan;14(1):36-49</Citation><ArticleIdList><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Xenobiotica. 1988 Apr;18(4):459-70</Citation><ArticleIdList><ArticleId IdType="pubmed">3135672</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23635029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Blood Med. 2014 Jun 12;5:69-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24966707</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2019 Feb 01;10:119</Citation><ArticleIdList><ArticleId IdType="pubmed">30774631</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Apr 10;334(2):306-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15780881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Mar 27;11(1):1620</Citation><ArticleIdList><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2019 Jul;28(7):573-581</Citation><ArticleIdList><ArticleId IdType="pubmed">31208237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr;92(4):424-432</Citation><ArticleIdList><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32271376</ArticleId></ArticleIdList></Reference><Reference><Citation>BioDrugs. 2019 Feb;33(1):15-32</Citation><ArticleIdList><ArticleId IdType="pubmed">30701418</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Sci. 2006 Jan;13(1):59-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16228284</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2017 Jan;25(1):35-48</Citation><ArticleIdList><ArticleId IdType="pubmed">27743750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 Jul;17(7):765-767</Citation><ArticleIdList><ArticleId IdType="pubmed">32047258</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncology. 2020;98(3):131-137</Citation><ArticleIdList><ArticleId IdType="pubmed">31958792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001962 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001962 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32299202
|texte= COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32299202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |